LB-1410

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug NameLB-1410
Drug Alias Name注射用LB1410LB-1410
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitorsAnti-Programmed death-ligand 1T lymphocytes stimulants
TargetsHepatitis A virus cellular receptor 2Programmed death-ligand 1
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesL&L Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesL&L Biopharma (Ningbo) Co LtdL&L Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsLymphoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A